Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personalised medicines

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

- PMLiVE

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Approximately 400 patients are expected to benefit from the treatment in England and Wales annually

- PMLiVE

NICE recommends GSK’s Zejula for patients with ovarian cancer

In the UK there are over 40,000 women with ovarian cancer

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

- PMLiVE

UK’s NICE recommends Roche’s Evrysdi

The first oral therapy for the leading genetic cause of death among babies and young children will be available to 1,500 people in England after Roche signed a price-cutting deal

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

- PMLiVE

NICE recommends Novartis’ Adakveo for sickle cell disease

The treatment for sickle cell disease is the first in more than 20 years

- PMLiVE

Future of MHRA uncertain amid Brexit-fuelled shake up

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions

- PMLiVE

UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

The approval for the Novartis drug by the NHS gatekeeper could save 30,000 lives over 10 years

- PMLiVE

NICE recommends Novartis’ Rydapt for advanced SM treatment

The twice-daily, oral drug improves overall survival of people with the rare blood disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links